Strategic Funding Leverage their notable backers (Cargill and Gates Foundation) to position joint development opportunities, grant-aligned programs, or co-investment pilots in infant nutrition and microbiome research.

Leadership Growth With a new CEO focused on growth, tailor outreach around scalable partnerships, rapid market expansion plans, and commercialization strategies for INF108-based interventions in neonatal care and early-life health.

Clinical Target Focus on neonatal health stakeholders—neonatologists, NICUs, pediatric nutritionists—where INF108 and B. infantis EVC001-related products could address NEC prevention and immune development, aligning with hospital procurement cycles.

Regulatory & Compliance Position opportunities around FDA/biologics or infant nutrition regulatory pathways, offering implementation for clinical studies, real-world evidence, and safety/efficacy data to accelerate adoption.

Comparable Landscape Benchmark against peers with similar funding and smaller headcounts to craft accessible collaboration models (pilot programs, co-development, or licensing) that fit a lean biotech startup seeking rapid, measured scale.